Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial

PURPOSE: The phase III DATA study compared 6 and 3 years of adjuvant anastrozole following 2–3 years of tamoxifen in postmenopausal breast cancer patients. This pre-planned side-study assessed the relationship between a reduced bone mineral density (BMD) and distant recurrence-free survival (DRFS),...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Breast Cancer Res Treat
Asıl Yazarlar: van Hellemond, Irene E. G., Smorenburg, Carolien H., Peer, Petronella G. M., Swinkels, Astrid C. P., Seynaeve, Caroline M., van der Sangen, Maurice J. C., Kroep, Judith R., de Graaf, Hiltje, Honkoop, Aafke H., Erdkamp, Frans L. G., van den Berkmortel, Franchette W. P. J., de Roos, Wilfred K., Linn, Sabine C., Imholz, Alexander L. T., de Boer, Maaike, Tjan-Heijnen, Vivianne C. G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer US 2020
Konular:
Clinical Trial
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7103013/
https://ncbi.nlm.nih.gov/pubmed/32124136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05567-9
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller